Johnson & Johnson (JNJ) shares are trading against the backdrop of a fresh U.S. Food and Drug Administration approval for Imaavy, the first and only treatment specifically cleared for warm autoimmune hemolytic anemia.

Despite the short term share price pullback of around 1% on the day of the Imaavy announcement, Johnson & Johnson’s recent approvals in wAIHA and atrial fibrillation come against a stronger backdrop. The 90 day share price return of 16.98% and the 1 year total shareholder return of 56.17% indicate momentum that has been building rather than fading.

Scan 51 high quality undervalued stocks that pair Johnson & Johnson style resilience in healthcare with current share prices that analysts flag as trading below intrinsic value.

Johnson & Johnson now trades only slightly below the average analyst price target, yet at a much steeper discount to some intrinsic value estimates. Is the market rightly cautious after the latest legal headlines, or is it mispricing that 25.88% gap?

Most Popular Narrative: 9.6% Overvalued

Johnson & Johnson closed at $270, which sits above the fair value of $246.46 in the most followed narrative and frames the debate around its recent strength.

Johnson & Johnson represents a high-quality, defensive healthcare leader with resilient earnings, strong cash flow generation, and disciplined capital allocation. Following the Kenvue spin-off, JNJ is now more focused on higher-margin Pharmaceutical and MedTech segments, improving long-term growth visibility.

Read the Read the complete narrative.

Want to understand why this narrative still points to upside from consistent revenue growth and premium margins? Curious how a richer future earnings multiple underpins the $246.46 fair value?

Result: Fair Value of $246.46 (OVERVALUED)

However, this Johnson & Johnson narrative could be knocked off course if litigation outcomes worsen or if key Pharmaceutical and MedTech products underperform expectations.

Another View On Johnson & Johnson’s Valuation

While the most followed Johnson & Johnson narrative points to a fair value of $246.46 and labels the stock as overvalued, the SWS DCF model presents a different perspective. At $270, Johnson & Johnson is shown as trading below an estimated future cash flow value of $364.27, which would suggest the shares are undervalued instead.

This gap between a $246.46 fair value and a $364.27 DCF estimate raises a practical question for investors. Is the market giving too much weight to recent earnings softness and legal risk, or is the cash flow model giving too much credit to long term resilience and growth assumptions?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Johnson & Johnson for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The mixed signals around Johnson & Johnson’s valuation and legal backdrop make this a moment to act, not to wait passively. Review the underlying data, weigh both the potential upsides and the legal or operational questions, and then ground your own view using the 2 key rewards and 1 important warning sign.

Looking for more Johnson & Johnson style investment ideas?

If Johnson & Johnson’s mix of resilience and opportunity appeals to you, do not stop here. Broaden your watchlist with other ideas that fit your goals.

• Target stability and value by reviewing companies that appear attractively priced on fundamentals using the 51 high quality undervalued stocks.
• Strengthen your income stream by focusing on reliable payers through the 11 dividend fortresses.
• Protect your capital by filtering for companies with robust finances and low perceived risk using the 75 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.